// App-Quantinova.ai

2120 : Interim Cell-Free Circulating Lymphoma DNA Analysis of the Phase 2 Accept Trial

Researchers

Presenter

  • Anthony Cutts

Principal Investigators

  • Edward Wilson

  • Pek Sang Tang

  • Andrew Davies

  • Peter Johnson

  • Louise Stanton

  • Katy Mercer

  • Josh Caddy

  • Anna Schuh

  • Laura Lopez Pascua

  • Helene Marie-Pierre Dreau

Medical Centers

  • Department of Oncology, University of Oxford, Oxford, United Kingdom

  • Department of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

  • St Vincents Hospital, University of Melbourne, Melbourne, Victoria, Australia

  • Cancer Research UK/NIHR Experimental Cancer Medicines Centre, University of Southampton,Southampton,United Kingdom

  • Southampton General Hospital School of Medicine, Southampton, United Kingdom

  • Southampton Clinical Trials Unit,University of Southampton, Southampton, United Kingdom

  • Oxford Respiratory Trials Unit, Oxford University Hospital NHS Trust, Oxford, United Kingdom,

  • Molecular Diagnostic Centre, Department of Oncology,University of Oxford,Oxford,United Kingdom

  • Department of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

Locations

  • United Kingdom

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lymphomas

  • Solid malignancies

Biomarkers

  • Circulating DNA

  • Plasma cell-free DNA

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved